Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label toxicity. Show all posts
Showing posts with label toxicity. Show all posts
Monday, April 30, 2012

paywalled: Hematological Toxicity After Robotic Stereotactic Body Radiosurgery for Treatment of Metastatic Gynecologic Malignancies

›
Hematological Toxicity After Robotic Stereotactic Body Radiosurgery for Treatment of Metastatic Gynecologic Malignancies published online ...
Saturday, April 21, 2012

abstract: Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and non small cell lung cancer and its role in survival and toxicity.

›
  Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and no...
Tuesday, March 27, 2012

abstract: Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

›
Progression-free and overall survival of a modified outpatient regime... [Gynecol Oncol. 2012] - PubMed - NCBI Abstract OBJECTIVE: G...
Friday, March 02, 2012

Phase I Study of the Vascular-Disrupting Agent OXi4503

›
Phase I Study of the Vascular-Disrupting Agent OXi4503 : Purpose: Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, ...
Tuesday, February 21, 2012

Call for Changes in Clinical Trial Reporting of Older Patients With Cancer [Correspondence] opens in pdf file

›
"In studies in which older patients make up a significant proportion (>15%) of the study population, an analysis of the possible int...
Wednesday, February 08, 2012

open access: Pharmaceutical care for patients with breast and ovarian cancer - adverse drug events

›
Blogger's Note:  'tag' line includes breast cancer only; study included few ovarian cancer patients Conclusions   In con...
Wednesday, January 25, 2012

abstract: Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer

›
Objective: The purpose of this review was to provide an overview of angiogenesis, including the rationale for targeting angiogenesis ...
Sunday, January 22, 2012

abstract: Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review

›
"Due to the small number of randomized controlled trials conducted in the field of EGFR inhibitor-induced skin toxicity so far, it is...
Monday, February 21, 2011

Letter to the Editor: Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer

›
Note : no abstract/pay-per-view (subscription req'd $$$)
Saturday, October 09, 2010

abstract: Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure — JCO

›
Purpose Area under the curve (AUC) dosing is routinely carried out for carboplatin , but the chosen target AUC values remain largely em...
Sunday, August 22, 2010

(abstract) From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer — Ann Oncol

›
Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-sect...
Tuesday, July 20, 2010

Overcoming TRAIL resistance in ovarian carcinoma

›
CONCLUSION: Continued efforts with combination therapy designed to target multiple steps in apoptotic pathways may not only improve the eff...
Saturday, July 17, 2010

Abstract/full acess: Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

›
Background: Hypertension (HT) and hand-foot skin reactions (HFSR) may be related to the activity of bevacizumab and sorafenib. We hypothesi...
Tuesday, June 29, 2010

Oncologist preferences for health States associated with the treatment of advanced ovarian cancer - (interview with 34 oncologists) - abstract

›
Objective: "To explore oncologists' preferences for hypothetical outcome scenarios (i.e. health states) resulting from various t...
Wednesday, May 05, 2010

2010: Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer : The Lancet Oncology (abstract only)

›
Note: abstract/full access is by subscription/$$
Monday, April 12, 2010

commentary/Japanese study - Carbo/Taxol - Dose-Dense Chemotherapy for Ovarian Cancer - National Cancer Institute

›
"...Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard ...
Friday, January 01, 2010

Guidelines for the management of ovarian cancer during pregnancy.

›
"If chemotherapy is indicated, we recommend delaying administration, if possible, until after the delivery or at least after 20 weeks i...